The prognostic significance of the BRAFV600E mutation in papillary thyroid carcinoma detected by mutation-specific immunohistochemistry
References (49)
- et al.
Thyroid cancer epidemiology and prognostic variables
Clin Oncol (R Coll Radiol)
(2010) - et al.
BRAF(V600E) mutation analysis of liquid-based preparation-processed fine needle aspiration sample improves the diagnostic rate of papillary thyroid carcinoma
Hum Pathol
(2012) - et al.
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses
Blood
(2012) - et al.
BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis
Blood
(2012) - et al.
Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing
J Mol Diagn
(2013) - et al.
Immunohistochemistry with a mutation- specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma
Mod Pathol
(2013) - et al.
Detection ofBRAFV600E mutations in skin metastases of malignant melanoma by monoclonal antibody VE1
J Am Acad Dermatol
(2012) - et al.
Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immuno- histochemistry with a mutation-specific monoclonal antibody and allele- specific PCR
Hum Pathol
(2013) - et al.
Diagnostic value of immunohisto- chemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients
Ann Oncol
(2013) - et al.
BRAF mutations in metanephric adenoma of the kidney
Eur Urol
(2012)
Papillary thyroid carcinoma: an update
Mod Pathol
Molecular genotyping of papillary thyroid carcinoma follicular variant according to its histological subtypes (encapsulated vs infiltrative) reveals distinct BRAF and RAS mutation patterns
Mod Pathol
Comparison of allelic discrimination by dHPLC, HRM, and TaqMan in the detection of BRAF mutation V600E
J Mol Diagn
Correlation between BRAF mutation and the clinicopathological parameters in papillary thyroid carcinoma with particular reference to follicular variant
Hum Pathol
A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S. 1985-1995
Cancer
Pathological tumor-nodemetastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients
J ClinEndocrinolMetab
International patterns and trends in thyroid cancer incidence, 1973-2002
Cancer Causes Control
Increasing incidence of thyroid cancer in the United States, 1973-2002
JAMA
BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications
Endocr Rev
Aberrant B-Raf signaling in human cancer - 10 years from bench to bedside
Crit Rev Oncog
The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis
Cancer
BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis
Medicine (Baltimore)
Molecular pathogenesis and mechanisms of thyroid cancer
Nat Rev Cancer
Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody
Acta Neuropathol
Cited by (33)
Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma
2018, Pathology Research and PracticeCitation Excerpt :Although the VE1 monoclonal antibody has been shown to be a highly sensitive and specific antibody for the immunohistochemical detection of BRAF V600E mutation in a variety of primary and metastatic tumors, a full and practical standard in clinical setting has not been done [19]. The sensitivities range from 89% to 100% and specificities range from 61.5% to 100% in PTC [14,15,19,25–32]. The optimal scoring criteria for this antibody in PTC specimens are not well defined.
Use of monoclonal antibodies to detect specific mutations in formalin-fixed, paraffin-embedded tissue sections
2016, Human PathologyCitation Excerpt :Generally, VE1 immunostaining of a cytology specimen is less specific than that of a surgical specimen for detection of the BRAF V600E mutation [70,71]. BRAF mutation in PTC determined by IHC is associated with significantly increased risk of lymph node recurrence [72]. Succinate dehydrogenase (SDH) mutations in one of the SDH genes lead to succinate accumulation and very low fumarate levels.
Immunohistochemical detection of NRAS<sup>Q61R</sup> protein in follicular-patterned thyroid tumors
2016, Human PathologyCitation Excerpt :Some mutation-specific antibodies are recently available for immunohistochemistry (IHC) performed on formalin-fixed, paraffin-embedded (FFPE) tissue sections. For example, the antibody VE1 for BRAFV600E is a useful and reliable tool for BRAFT1799A detection in thyroid lesions, especially in PTC [9–13]. There is also a newly developed mutation-specific antibody for NRASQ61R that appears to be a powerful detection tool for the mutation in malignant melanoma [14,15].
BRAF V600E mutation-specific antibody: A review
2015, Seminars in Diagnostic PathologyCitation Excerpt :There is some indication that vemurafenib produces a clinical response in patients with BRAF V600E-mutant metastatic PTC and could even have efficacy in the setting of anaplastic thyroid carcinoma harboring a BRAF mutation.54,55 IHC with the VE1 antibody has demonstrated a high concordance rate with molecular methods with sensitivities ranging from 89% to 100% and specificities from 61.5% to 100% in FFPE tissue from PTC specimens (Table).21,39,46,56–64 An example of a PTC harboring a BRAF V600E mutation stained for BRAF V600E is shown in Fig. B.
Risk of malignancy for each Bethesda class in pediatric thyroid nodules
2015, Journal of Pediatric SurgeryCitation Excerpt :Therefore the adult guidelines for BV lesions are reasonable for children, and each case must be individually tailored depending on other risk factors, concomitant contralateral thyroid disease, patient wishes etc. For BIV nodules, the rate of papillary thyroid cancer was 50 per cent and frozen section, which may be able to definitively diagnose papillary carcinoma, may therefore have a much higher yield to confirm cancer than in adult BIV nodules, where less than 15 per cent will be papillary thyroid cancers [11–18]. The diagnostic dilemma of BIII nodules in adults seems to be equally challenging in pediatric patients with a malignancy risk of around 18 per cent.
- ‡
these authors contributed equally